This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Must be able to understand and provide written informed consent
Age 18 or older
Clinical diagnosis of cutaneous warts
Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)
Untreated cutaneous warts
Anogenital warts
Oral warts
Treatment for cutaneous warts in the past 4 weeks
Western Institute for Veterans Research
Lead sponsor
University of Utah
Collaborator
Merck Sharp & Dohme LLC
Collaborator